NEW TRENDS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND CARCINOMA OF THE PROSTATE

被引:13
|
作者
PETROVICH, Z
AMEYE, F
BAERT, L
BICHLER, KH
BOYD, SD
BRADY, LW
BRUSKEWITZ, RC
DIXON, C
PERRIN, P
WATSON, GM
机构
[1] UNIV SO CALIF,SCH MED,DEPT RADIAT ONCOL & UROL,LOS ANGELES,CA 90033
[2] CATHOLIC UNIV LEUVEN,DEPT UROL,B-3000 LOUVAIN,BELGIUM
[3] UNIV TUBINGEN,DEPT RADIAT ONCOL & NUCL MED,W-7400 TUBINGEN 1,GERMANY
[4] HAHNEMANN UNIV,DEPT UROL,PHILADELPHIA,PA 19102
[5] UNIV WISCONSIN,DEPT UROL,MADISON,WI 53706
[6] MED COLL WISCONSIN,DEPT UROL,MILWAUKEE,WI 53226
[7] HOP ANTIQUAILLE,DEPT UROL,F-69321 LYON 1,FRANCE
[8] LONDON INST UROL,LONDON,ENGLAND
关键词
TREATMENT OF BPH; PROSTATE CANCER;
D O I
10.1097/00000421-199306000-00002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Benign prostatic hyperplasia (BPH) is a very common condition affecting over 800.000 American males each year. A standard, effective, and well-proven therapy is prostatectomy. This surgical procedure is used to treat, in the United States, approximately 400.000 BPH patients annually. Major treatment benefit is expected in 70% to 80% of patients. Complications are seen in 20% of the surgically treated patients. Due to the advanced age of BPH patients and the presence of other serious coexisting medical problems, surgical therapy may be difficult to utilize. These patients, who present a high risk for surgery, are in need of alternative treatments. Alternative therapy in BPH patients with clinically important symptoms and signs of urinary outflow obstruction include treatment with pharmacological agents, balloon dilatation, laser beam therapy, transurethral thermal therapy, transrectal microwave hyperthermia, and transurethral microwave hyperthermia. These alternative treatment modalities are currently under intensive study. These new treatment modalities ultimately must be compared with the standard treatment, which is prostatectomy. Due to the unpredictable natural history of BPH, it is desirable that each Phase III study should contain a no-treatment observation-only arm. Adenocarcinoma of the prostate (CaP) has become a tumor, which first in frequency, and second in importance in cancer mortality statistics of American males. Local tumor control rates and long-term survivals, with radical prostatectomy or radiation therapy, have been excellent. There was, however, recent concern regarding a high incidence of microscopic local tumor recurrence following a definitive course of irradiation. Deep regional or intracavitary hyperthermia (HT) with phase steering may be of value as an adjuvant treatment to radiotherapy. This HT may increase the incidence of local tumor control obtained with radiotherapy. Phase I-II clinical studies are currently under-way.
引用
收藏
页码:187 / 200
页数:14
相关论文
共 50 条
  • [31] Benign prostatic hyperplasia and prostate cancer
    Guess, HA
    EPIDEMIOLOGIC REVIEWS, 2001, 23 (01) : 152 - 158
  • [32] Benign prostatic hyperplasia (the aging prostate)
    Medina, JJ
    Parra, RO
    Moore, RG
    MEDICAL CLINICS OF NORTH AMERICA, 1999, 83 (05) : 1213 - +
  • [33] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2015, 25 (02): : F58 - F60
  • [34] Benign prostatic hyperplasia, prostate cancer
    Masson-Lecomte, A.
    PROGRES EN UROLOGIE, 2014, 24 (01): : F27 - F30
  • [35] Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer
    Cicero, Arrigo F. G.
    Allkanjari, Olta
    Busetto, Gian Maria
    Cai, Tommaso
    Largana, Gaetano
    Magri, Vittorio
    Perletti, Gianpaolo
    Della Cuna, Francesco Saverio Robustelli
    Russo, Giorgio Ivan
    Stamatiou, Kostantinos
    Trinchieri, Alberto
    Vitalone, Annabella
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2019, 91 (03) : 139 - 152
  • [36] Prostate specific antigen (PSA) levels in health, prostatic carcinoma and benign prostatic hyperplasia
    Dosoo, D. K.
    Botchway, F. A.
    Adu-Gyamfi, C.
    Amanquah, S. D.
    CLINICAL CHEMISTRY, 2006, 52 (06) : A166 - A166
  • [37] PROSTATE-SPECIFIC ANTIGEN IN THE EXPRESSED PROSTATIC FLUID OF MEN WITH BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CARCINOMA
    KIM, ED
    SMITH, ND
    GRAYHACK, JT
    JOURNAL OF UROLOGY, 1995, 154 (05): : 1802 - 1805
  • [38] A (new) revolution in the treatment of benign prostatic hyperplasia? Aqua-ablation and prostate embolization
    Netsch, C.
    Abt, D.
    Rieken, M.
    Gross, A. J.
    UROLOGE, 2020, 59 (10): : 1177 - 1186
  • [39] Prevalence of linea nigra in patients with benign prostatic hyperplasia and prostate carcinoma
    Okeke, Linus Ikechukwu
    George, Adekunle Olufemi
    Ogunbiyi, Adebola Olufunmilayo
    Wachtel, Mitchelle
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2012, 51 : 41 - 43
  • [40] URINARY CHOLESTEROL EXCRETION IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND CARCINOMA OF THE PROSTATE
    JUENGST, D
    PICKEL, A
    ELSAESSER, E
    MARX, FJ
    KARL, HJ
    CANCER, 1979, 43 (01) : 353 - 359